AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
AlloVir, Inc. (ALVR)
Company Research
Source: GlobeNewswire
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases Invented by VEGF pioneer Dr. Napoleone Ferrara, TH103 has demonstrated longer-acting and increased anti-VEGF activity in head-to-head preclinical studies against aflibercept, and could potentially provide a meaningful advance in treatment in the global $14 billion branded anti-VEGF retinal market TH103 is in a Phase 1 clinical trial in patients with neovascular age-related macular degeneration with initial data expected in Q3 2025 The combined company is expected to have a cash balance of approximately $100 million at close, which is anticipated in Q1 2025. Transaction expected to provide cash runway into Q4 2026 Companies to host webcast today, November 8, 2024 at 8:30 a.m. ET WALTHAM, Mass. and PALO ALTO, Calif., Nov. 08, 2024 (GLOBE
Show less
Read more
Impact Snapshot
Event Time:
ALVR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALVR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALVR alerts
High impacting AlloVir, Inc. news events
Weekly update
A roundup of the hottest topics
ALVR
News
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ALVR, AEGlobeNewswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, STAF, NBR, ALVR on Behalf of ShareholdersGlobeNewswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENLC, ALVR, CYTH on Behalf of ShareholdersGlobeNewswire
- $HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of ENLC, ALVR, and CYTHPR Newswire
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALVR, STAF, AE on Behalf of ShareholdersGlobeNewswire
ALVR
Earnings
- 11/12/24 - Beat
ALVR
Sec Filings
- 12/20/24 - Form 425
- 12/20/24 - Form 8-K
- 12/11/24 - Form 4
- ALVR's page on the SEC website